Lilly cuts jobs in Ireland
pharmafile | May 23, 2011 | News story | Manufacturing and Production |Â Â Ireland, job cuts, lilly, manufacturing and productionÂ
Eli Lilly has said it is downsizing its plant in County Cork, Ireland, by around 14% in light of patent losses on some of its key products and a generally “challenging environment” for the pharmaceutical industry.
Between 60 and 70 jobs are to go at the Kinsale plant in Dunderrow, which currently has a workforce of around 460 staff. The move reverses a recruitment drive which sought to add 200 staff to the plant and was announced in 2009, when the plant employed around 400 staff.
The Kinsale facility has been subject to a major overhaul and expansion operation in recent years, with $400 million spent on a new 158,000 sq.ft. biologic drugs manufacturing plant and upgraded small-molecule production units.
It has been run by Lilly since the early 1980s and is one of six bulk manufacturing plants operated by the company worldwide, making a range of products which are exported to fill-finish plants supplying worldwide markets.
Its two major small-molecule products are Zyprexa (olanzapine), Lilly’s treatment for schizophrenia, and Evista (raloxifene) for osteoporosis prevention. Both Zyprexa and Evista will start to lose patent protection next year, putting a sizeable chunk of Lilly’s revenues under threat.
Sales of Zyprexa in 2010 topped $5 billion – accounting for more than a fifth of Lilly’s total revenues – while Evista added another $1 billion to the company’s coffers.
Lilly said its other operations in Cork, Dublin and Sligo will not be affected by the cutbacks, which it hopes to achieve through a programme of voluntary redundancies.
Earlier this year, the company officially opened a new European Financial Shared Services Centre in Cork to support its European operations with general accounting, order-to-cash and purchase-to-pay activities.
Phil Taylor
Related Content
Rotzinger launches modular filling and capping platform for over-the-counter products
Rotzinger PharmaPack has launched a new filling and capping platform called VarioFill, designed to handle …
NICE RECOMMENDS LILLY’S TIRZEPATIDE (MOUNJARO ®▼) FOR MANAGING OVERWEIGHT AND OBESITY IN FINAL DRAFT GUIDANCE
BASINGSTOKE, 5th December 2024 – Eli Lilly and Company announced today that the National Institute …
Astellas plans to invest over €330m in new facility in Ireland
Astellas Pharma has announced that it is preparing to submit a planning application to build …
